Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

NCT05713994 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

PROCEDURE: HAIC
DRUG: Bevacizumab plus Atezolizumab
DRUG: Bevacizumab Biosimilar IBI305 plus sintilimab
DRUG: Lenvatinib
DRUG: Sorafenib
DRUG: Donafenib
DRUG: Regorafenib
DRUG: apatinib plus camrelizumab
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Ze-yang Ding, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]